JDP2 CRISPR/Cas9 KO Plasmid (h): sc-406888
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- JDP2 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the JDP2 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: JDP2 Antibody (3C1): sc-517133
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
JDP2 CRISPR/Cas9 KO Plasmid (h) | sc-406888 | 20 µg | $397.00 |
Overview
JDP2 (Jun dimerization protein 2) is a basic leucine zipper transcription factor that modulates AP-1–dependent gene expression by heterodimerizing with JUN/FOS family members and influencing chromatin structure through interactions with histone-modifying complexes. It functions as a context-dependent regulator of cellular programs including differentiation, cell-cycle control, stress responses, and apoptosis, with reported roles in oxidative stress signaling and inflammatory transcriptional networks. By shaping transcriptional outputs downstream of MAPK and other stimulus-responsive pathways, JDP2 contributes to lineage commitment and adaptive responses to environmental cues. Dysregulated JDP2 expression or activity has been associated with altered proliferation and survival phenotypes relevant to cancer biology and immune-related processes, making it a useful node for mechanistic studies of transcriptional regulation.
JDP2 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the JDP2 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the JDP2 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the JDP2 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish JDP2 protein expression.
This CRISPR knockout system enables efficient generation of JDP2-deficient cell models for investigation of JDP2 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting JDP2 exon(s) critical for JDP2 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple JDP2 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by JDP2 CRISPR/Cas9 KO Plasmid (h) and JDP2 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the JDP2 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by JDP2 HDR Plasmid (h) and JDP2 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by JDP2 homology arms to support homology-directed repair at defined JDP2 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.